NEW YORK (GenomeWeb) – Thermo Fisher Scientific and BioAnalytix today announced they will develop advanced analytical profiling platforms and applications for characterizing biologic and biosimilar drugs.
Minor differences in the structures of biological drugs can significantly affect their safety and efficacy, and sophisticated analytic workflows are necessary for accurate characterization. Thermo Fisher and BioAnalytix aim to develop analytical profiling standards in order to support and accelerate the development of such therapeutics, they said.
As part of the effort, researchers at BioAnalytix will use Thermo Fisher's Orbitrap-based mass spectrometers, sample preparation, separation and enrichment standards, reagents, and software, the firms said.
Financial and other terms of the deal were not disclosed.
Based in Cambridge, Mass., BioAnalytix was spun out from the Barnett Institute of Chemical and Biological Analysis at Northeastern University in 2012 and works with pharmaceutical firms to develop and apply analytical methods and data for the development of biologic therapeutics.